Patent ID: 6417394
Filing Date: 2002-07-09
Classification: A61P,C07C

Abstract:
A compound according to Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:the pharmaceutically acceptable salt form is selected from the group: diethylamine, dicyclohexylamine, meglumine and lysine; R1 is (CH2)nCR5&boxH;CR6R7; R2 is selected from the group: H, CH3, OH, OCH3, OCH2CH3, and CH2(CH3)2; R3 is selected from the group: H, CH3, OH, OCH3, OCH2CH3, and CH2(CH3)2; R4 is selected from the group: CN, NO2, CH3, CH2CH3, CH2CH2Y and Y; R5 and R6 are independently at each occurrence selected from the group: H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, XC1-3 alkyl, XC2-4 alkenyl, XC2-4 alkynyl and Y; R7 is independently at each occurrence selected from the group: CN, C1-4 alkyl-OH, C(O)NR10R11, C(O)NR12R13, C(O)(O)(R)12, C(O)NHC(O)R12, CO(NH2)(NOR12), C(O)NHCH2R12, C(NH2)(NOR12), S(O)R12, S(O)(O)(OR12), S(O)(O)(NHCO2R12), PO3R12, P(O)(NR12R13)(NR12R13), P(O)(NR12R13)(OR14), CONR12(CH2)qOCH3, CONR12(CH2)qNR8R9, and oxadiazole substituted with CH3; R8 and R9 are independently at each occurrence selected from the group: C1-7 alkyl, C3-7 cycloalkyl, Oâ€”C1-7 alkyl, C1-7 alkyl-Y, and phenyl; R10 and R11 are independently CH3 or C2H5, or taken together form a morpholino group bonded via its nitrogen atom; R12 and R13 and R14 are independently at each occurrence selected from the group: H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, Oâ€”C1-12 alkyl, Oâ€”C2-12 alkenyl, Oâ€”C2-12 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkenyl, linear and cyclic heteroalkyl, aryl, heteroaryl, and Y; X is selected from the group: O and S; Y is selected from the group: F, Cl, Br, and I; n is selected from: 0, 1, and 2; q is selected from the group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.